Literature DB >> 19679679

Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition.

Benjamin Keserü1, Eduardo Barbosa-Sicard, Ralph T Schermuly, Hiromasa Tanaka, Bruce D Hammock, Norbert Weissmann, Beate Fisslthaler, Ingrid Fleming.   

Abstract

AIMS: The C-terminal domain of the soluble epoxide hydrolase (sEH) metabolizes epoxyeicosatrienoic acids (EETs) to their less active diols, while the N-terminal domain demonstrates lipid phosphatase activity. As EETs are potent vasoconstrictors in the pulmonary circulation, we assessed the development of pulmonary hypertension induced by exposure to hypoxia (10% O(2)) for 21 days in wild-type (WT) and sEH(-/-) mice and compared the effects with chronic (4 months) sEH inhibition. METHODS AND
RESULTS: In isolated lungs from WT mice, acute hypoxic vasoconstriction (HPV) was potentiated by sEH inhibition and attenuated by an EET antagonist. After prolonged hypoxia, the acute HPV and sensitivity to the EET antagonist were increased, but potentiation of vasoconstriction following sEH inhibition was not evident. Chronic hypoxia also stimulated the muscularization of pulmonary arteries and decreased sEH expression in WT mice. In normoxic sEH(-/-) mice, acute HPV and small artery muscularization were greater than that in WT lungs and enhanced muscularization was accompanied with decreased voluntary exercise capacity. Acute HPV in sEH(-/-) mice was insensitive to sEH inhibition but inhibited by the EET antagonist and chronic hypoxia induced an exaggerated pulmonary vascular remodelling. In WT mice, chronic sEH inhibition increased serum EET levels but failed to affect acute HPV, right ventricle weight, pulmonary artery muscularization, or voluntary running distance. In human donor lungs, the sEH was expressed in the wall of pulmonary arteries, however, sEH expression was absent in samples from patients with pulmonary hypertension.
CONCLUSION: These data suggest that a decrease in sEH expression is intimately linked to pathophysiology of hypoxia-induced pulmonary remodelling and hypertension. However, as sEH inhibitors do not promote the development of pulmonary hypertension it seems likely that the N-terminal lipid phosphatase may play a role in the development of this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19679679      PMCID: PMC2860707          DOI: 10.1093/cvr/cvp281

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  38 in total

1.  Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis.

Authors:  Ahmed E Enayetallah; David F Grant
Journal:  Biochem Biophys Res Commun       Date:  2006-01-10       Impact factor: 3.575

2.  Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4.

Authors:  Anke C Webler; Rüdiger Popp; Thomas Korff; U Ruth Michaelis; Carmen Urbich; Rudi Busse; Ingrid Fleming
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-13       Impact factor: 8.311

3.  Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2.

Authors:  Hiromasa Tanaka; Shizuo G Kamita; Nicola M Wolf; Todd R Harris; Zhaoju Wu; Christophe Morisseau; Bruce D Hammock
Journal:  Biochim Biophys Acta       Date:  2007-12-03

4.  Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation.

Authors:  Michael P Hutchens; Takaaki Nakano; Jennifer Dunlap; Richard J Traystman; Patricia D Hurn; Nabil J Alkayed
Journal:  Resuscitation       Date:  2007-08-28       Impact factor: 5.262

5.  Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.

Authors:  Marc Revermann; Eduardo Barbosa-Sicard; Eva Dony; Ralph T Schermuly; Christophe Morisseau; Gerd Geisslinger; Ingrid Fleming; Bruce D Hammock; Ralf P Brandes
Journal:  J Hypertens       Date:  2009-02       Impact factor: 4.844

6.  Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Authors:  Sung Hee Hwang; Hsing-Ju Tsai; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2007-07-06       Impact factor: 7.446

7.  Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase.

Authors:  Ahmed E EnayetAllah; Ayala Luria; Beibei Luo; Hsing-Ju Tsai; Priyanka Sura; Bruce D Hammock; David F Grant
Journal:  J Biol Chem       Date:  2008-10-29       Impact factor: 5.157

8.  Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response.

Authors:  Benjamin Keserü; Eduardo Barbosa-Sicard; Rüdiger Popp; Beate Fisslthaler; Alexander Dietrich; Thomas Gudermann; Bruce D Hammock; John R Falck; Norbert Weissmann; Rudi Busse; Ingrid Fleming
Journal:  FASEB J       Date:  2008-08-25       Impact factor: 5.191

9.  Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans.

Authors:  Andreas Gschwendtner; Stephan Ripke; Tobias Freilinger; Peter Lichtner; Bertram Müller-Myhsok; H-Erich Wichmann; Thomas Meitinger; Martin Dichgans
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914

10.  Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.

Authors:  Mandi J Corenblum; Vance E Wise; Katrin Georgi; Bruce D Hammock; Peter A Doris; Myriam Fornage
Journal:  Hypertension       Date:  2007-12-17       Impact factor: 10.190

View more
  38 in total

1.  Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols.

Authors:  Timo Frömel; Benno Jungblut; Jiong Hu; Caroline Trouvain; Eduardo Barbosa-Sicard; Rüdiger Popp; Stefan Liebner; Stefanie Dimmeler; Bruce D Hammock; Ingrid Fleming
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase.

Authors:  Hsin-Han Hou; Bruce D Hammock; Kou-Hui Su; Christophe Morisseau; Yu Ru Kou; Susumu Imaoka; Ami Oguro; Song-Kun Shyue; Jin-Feng Zhao; Tzong-Shyuan Lee
Journal:  Cardiovasc Res       Date:  2011-11-08       Impact factor: 10.787

Review 3.  Connexins and gap junctions in the EDHF phenomenon and conducted vasomotor responses.

Authors:  Cor de Wit; Tudor M Griffith
Journal:  Pflugers Arch       Date:  2010-04-09       Impact factor: 3.657

4.  Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids.

Authors:  Christophe Morisseau; Nils Helge Schebb; Hua Dong; Arzu Ulu; Pavel A Aronov; Bruce D Hammock
Journal:  Biochem Biophys Res Commun       Date:  2012-02-24       Impact factor: 3.575

5.  Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice.

Authors:  Jun Yang; Jennifer Bratt; Lisa Franzi; Jun-Yan Liu; Guodong Zhang; Amir A Zeki; Christoph F A Vogel; Keisha Williams; Hua Dong; Yanping Lin; Sung Hee Hwang; Nicholas J Kenyon; Bruce D Hammock
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

Review 6.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

7.  Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke.

Authors:  Jafar Sadik B Shaik; Muzamil Ahmad; Wenjin Li; Marie E Rose; Lesley M Foley; T Kevin Hitchens; Steven H Graham; Sung Hee Hwang; Bruce D Hammock; Samuel M Poloyac
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-16       Impact factor: 4.733

Review 8.  Roles of the epoxygenase CYP2J2 in the endothelium.

Authors:  Ara Askari; Scott J Thomson; Matthew L Edin; Darryl C Zeldin; David Bishop-Bailey
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-03-06       Impact factor: 3.072

Review 9.  Soluble epoxide hydrolase: gene structure, expression and deletion.

Authors:  Todd R Harris; Bruce D Hammock
Journal:  Gene       Date:  2013-05-20       Impact factor: 3.688

10.  Development of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted libraries.

Authors:  Christophe Morisseau; Sunil Sahdeo; Gino Cortopassi; Bruce D Hammock
Journal:  Anal Biochem       Date:  2012-12-03       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.